IPSEN (OTCMKTS:IPSEY – Get Free Report) shares gapped up before the market opened on Wednesday. The stock had previously closed at $40.00, but opened at $42.9960. IPSEN shares last traded at $42.9960, with a volume of 298 shares changing hands.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on IPSEY shares. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.
Get Our Latest Analysis on IPSEY
IPSEN Price Performance
The stock has a 50 day moving average price of $44.38 and a two-hundred day moving average price of $46.03.
IPSEN Company Profile
Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.
The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.
See Also
- Five stocks we like better than IPSEN
- NextEra and Dominion Have a Deal—Now Comes the Hard Part
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
